Tesamorelin, abdominal fat and weight loss
The Tesamorelin 10mg Pen listing is distinct from the US medicine EGRIFTA WR. The US medicine is indicated to reduce excess abdominal fat in HIV-infected adults with lipodystrophy. It is not indicated for weight-loss management, and the label describes its effect as weight neutral. EGRIFTA WR prescribing information.
A statement about abdominal fat in HIV-associated lipodystrophy should not become a claim that the supplier pen causes general weight loss. EGRIFTA WR prescribing information.
How does tesamorelin work?
Tesamorelin is described in the EGRIFTA WR label as a synthetically produced human growth hormone-releasing-factor analogue. The label also says the medicine stimulates growth-hormone production and increases serum IGF-1. These details identify its endocrine context; they do not replace the restricted indication with a broader benefit claim. EGRIFTA WR prescribing information.
EGRIFTA WR glucose and diabetes warning
The same label warns that glucose intolerance or diabetes may develop. It is a warning for EGRIFTA WR, not a finding that this individual pen has been evaluated. EGRIFTA WR prescribing information.
Tesamorelin pen versus vial
The catalogue identifies a pre-filled pen with a 10mg amount. It does not establish equivalence to EGRIFTA WR or give that medicine's US indication to the supplier product. The amount is not a concentration or a clinical instruction. EGRIFTA WR prescribing information.
Compare the separately documented Tesamorelin 10MG vial for its own presentation identity. The tesamorelin guide provides a broader topic reference, while the exact HIV-lipodystrophy and weight-neutral qualifications remain attached to the medicine label. EGRIFTA WR prescribing information.
